Peptide Comparison
CJC-1295 (No DAC)vsTabimorelin
A modified growth hormone-releasing hormone that boosts your body's natural GH pulses for better recovery, deeper sleep, and improved body composition.
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
At a Glance
Quick
comparison
Dose Range
CJC-1295 (No DAC)
100–100 mcg
Tabimorelin
1.5–1.5 mg/kg
Frequency
CJC-1295 (No DAC)
Once daily
Tabimorelin
Once daily
Administration
CJC-1295 (No DAC)
Subcutaneous injection
Tabimorelin
Oral (capsule or solution)
Cycle Length
CJC-1295 (No DAC)
8-12 weeks
Tabimorelin
4-6 weeks
Onset Speed
CJC-1295 (No DAC)
Moderate (1-2 weeks)
Tabimorelin
Moderate (1-2 weeks)
Evidence Level
CJC-1295 (No DAC)
Moderate human trials (Phase 1-2)
Tabimorelin
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
GH Stimulation
Sleep Quality
Recovery Support
Growth Hormone Stimulation
Convenience & Compliance
Selectivity & Safety Profile
Technical Data
Compound
specifications
CJC-1295 (No DAC)
Molecular Formula
C152H252N44O42
Molecular Weight
3367.9 g/mol
Half-Life
30 minutes to 2 hours
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
Tabimorelin
Molecular Formula
C32H40N4O3
Molecular Weight
528.7 g/mol
Half-Life
Several hours (exact human half-life not published; dose-dependent pharmacokinetics)
Bioavailability
Orally active with dose-dependent bioavailability (increases at higher doses)
CAS Number
193079-69-5
Protocols
Dosing
tiers
CJC-1295 (No DAC)
Tabimorelin
Applications
Best
suited for
CJC-1295 (No DAC)
Natural Growth Hormone Optimization
Perfect for those wanting to boost their body's own GH production rather than using synthetic growth hormone. Mimics the natural pulsatile release pattern your pituitary uses.
Workout Recovery and Muscle Building
Athletes and fitness enthusiasts use it to accelerate recovery between training sessions, support lean muscle development, and reduce body fat over time.
Sleep Quality Enhancement
Because GH is naturally released during deep sleep, many users report dramatically improved sleep quality with more vivid dreams and feeling more refreshed upon waking.
Anti-Aging and Vitality
As GH levels decline with age, CJC-1295 helps restore more youthful hormone patterns, potentially improving skin quality, energy levels, and overall well-being.
Synergistic Peptide Stacking
Designed to work hand-in-hand with GHRPs like Ipamorelin. When combined, these peptides amplify each other's effects for significantly greater GH release than either alone.
Tabimorelin
+Stimulates growth hormone release from the pituitary gland through ghrelin receptor activation
+Orally active—no injections required, making it convenient for daily use
+Dose-dependent growth hormone and IGF-1 elevation at therapeutic doses
+Does not significantly raise ACTH, cortisol, or prolactin at most doses, showing better selectivity than some competing GH-releasing peptides
+Well-tolerated in short-term human studies with generally mild adverse effects
Safety Profile
Side
effects
CJC-1295 (No DAC)
Common
- Injection site reactions
- Flushing or warmth
- Water retention
- Increased appetite
Uncommon
- Tingling or numbness
- Headache
Serious
- Allergic reaction
Tabimorelin
Common
- Headache
- Nausea
- Appetite stimulation
- Dizziness
- Dry mouth
Serious
- Drug-drug interactions via CYP3A4 inhibition
Research Status
Safety
& evidence
CJC-1295 (No DAC)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
CJC-1295 without DAC has been studied in Phase 1-2 human clinical trials with a favorable safety profile. The most common side effects are mild and include injection site reactions and temporary flushing. Because it stimulates natural GH release rather than providing exogenous GH, it maintains the body's feedback mechanisms.
Contraindications
- xActive cancer or history of cancer
- xPregnancy or breastfeeding
- xPituitary tumors or disorders
- xHypersensitivity to GHRH analogs
- xDiabetic retinopathy
Tabimorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.
Contraindications
- xActive or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
- xConcurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
- xUntreated thyroid dysfunction
- xUncontrolled diabetes
Decision Guide
Which is
right for you?
Choose CJC-1295 (No DAC) if...
- Increasing natural growth hormone levels
- Building lean muscle mass
- Improving sleep quality
- Enhancing workout recovery
Choose Tabimorelin if...
- Stimulating growth hormone production in healthy individuals
- Exploring GH secretagogue mechanisms in research settings
- Patients preferring oral administration over injections